NFE2L2 and hereditary leiomyomatosis and renal cell cancer: These co-altered candidates include multiple putative drug targets elevated in HLRCC versus NS patients, such as arsenic trioxide targeting the NRF2-target gene thioredoxin reductase (TXNRD1), as well as additional metabolic targets including the cyclic heptapeptide CAP-232 (TLN-232) targeting the glycolytic enzyme complex resident protein pyruvate kinase M2 (Table 3).